|Bid||295.94 x 800|
|Ask||300.10 x 800|
|Day's Range||294.31 - 298.73|
|52 Week Range||208.34 - 306.00|
|Beta (3Y Monthly)||1.15|
|PE Ratio (TTM)||33.29|
|Earnings Date||Jan. 28, 2020 - Feb. 3, 2020|
|Forward Dividend & Yield||0.76 (0.26%)|
|1y Target Est||314.80|
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target